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Background: Given the unceasing worldwide surge in COVID-19 cases, there is an imperative need to develop
highly specific and sensitive serology assays to define exposure to Severe Acute Respiratory Syndrome Coro-
navirus 2 (SARS-CoV-2).
Methods: Pooled plasma samples from PCR positive COVID-19 patients were used to identify linear B-cell epit-
opes from a SARS-CoV-2 peptide library of spike (S), envelope (E), membrane (M), and nucleocapsid (N) struc-
tural proteins by peptide-based ELISA. Hit epitopes were further validated with 79 COVID-19 patients with
different disease severity status, 13 seasonal human CoV, 20 recovered SARS patients and 22 healthy donors.
Findings: Four immunodominant epitopes, S14P5, S20P2, S21P2 and N4P5, were identified on the S and
N viral proteins. IgG responses to all identified epitopes displayed a strong detection profile, with N4P5
achieving the highest level of specificity (100%) and sensitivity (>96%) against SARS-CoV-2. Furthermore, the
magnitude of IgG responses to S14P5, S21P2 and N4P5 were strongly associated with disease severity.
Interpretation: IgG responses to the peptide epitopes can serve as useful indicators for the degree of immuno-
pathology in COVID-19 patients, and function as higly specific and sensitive sero-immunosurveillance tools
for recent or past SARS-CoV-2 infections. The flexibility of these epitopes to be used alone or in combination
will allow for the development of improved point-of-care-tests (POCTs).Keywords:
Epitopes
SARS-CoV-2
COVID-19
Patients
Biomarkersmunity, Singapore Immunol-
arch (A*STAR), 8A Biomedical
gapore.
. Ng).
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research in Context
Evidence before this study
We searched PubMed on March 30, 2020,
formed immunoassays on the detection
Coronavirus Disease 2019 (COVID-19).
were “COVID-1900, OR “SARS-CoV-200, AND
“serology”. While there were several re
assays using SARS-CoV-2 spike protein as
and nucleocapsid protein to identify CO
immunodominant linear B-cell epitopes on
have not been determined and validated
Moreover, serological approaches on using
sequences in combination to distinguish
from other seasonal coronavirus or heal
potential markers for severity-associated
were not reported.
Added value of this study
In our study, 81 patients from the Singapor
were screened for antibodies against linear
encompassing the entire SARS-CoV-2 stru
initial screening with pooled peptides (five
and pooled patient samples validated the
coronavirus spike and nucleocapsid protein
sation to identify immunodominant peptid
sequently demonstrated. Immunodomin
validated to be highly specific and sensit
SARS-CoV-2 infections from other coronav
over, several epitopes were found to be stro
COVID-19 severity. In addition to guiding
assessment, determining specific linear B-ce
a more targeted immune-based approach t
tein. Using these immunodominant peptid
nation would allow for the development of
sensitive immunoassay to detect individua
exposure to SARS-CoV-2. Ideally, the implem
on point-of-care tests would be more spec
than protein-based systems.
Implications of all the available evidence
Current immunoassays against SARS-CoV-
viral protein, which may be less specific a
giving rise to issues of false positive
highlighted the importance of using specifi
B-cell linear epitopes as a targeted appr
individuals with past or recent SARS-CoV-2
102912 S.N. Amrun et al. / EBioMedicine 58 (2020) 102911102919Funding: Biomedical Research Council (BMRC), the A*ccelerate GAP-funded project (ACCL/19-GAP064-R20H-
H) from Agency of Science, Technology and Research (A*STAR), and National Medical Research Council
(NMRC) COVID-19 Research fund (COVID19RF-001) and CCGSFPOR20002. ATR is supported by the Singapore
International Graduate Award (SINGA), A*STAR.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
The ongoing pandemic caused by Severe Acute Respiratory Syn-
drome Coronavirus 2 (SARS-CoV-2) [1] has resulted in more than
4.5 million confirmed human infection cases in 213 countries, with a
global mortality rate of almost 7% [2], which has led to partial or totalfor studies that per-
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erated major socio-economic disruptions worldwide, overwhelming
healthcare systems in both developed and developing countries.
While quantitative reverse transcriptase PCR (qRT-PCR) remains as a
gold standard for the early detection of SARS-CoV-2-infected individ-
uals, the incidence of false negative diagnosis due to insufficient viral
genetic material at the point of detection has limited such molecular-
based assays [3]. Although rapid tests to detect acute infections are
crucial in light of the current pandemic, it is also necessary to develop
efficient assays for the detection of exposure in order to successfully
mitigate virus transmission. Thus, there is an imperative need to rap-
idly develop highly specific and sensitive serology-based approaches
to confirm molecular diagnosis, and enable immunosurveillance to
identify individuals with recent or past exposure to SARS-CoV-2.
To date, several studies and pre-prints have described serological
assays to detect SARS-CoV-2-specific antibodies in patient blood
specimens [37]. These immunoassays primarily use recombinant
coronavirus proteins, spike (S), which is exposed on the surface of
the viral particle, and nucleocapsid (N), which is highly expressed
during infection [5, 8]. The wealth of findings from these studies has
shed some light on the general humoral response upon SARS-CoV-2
infection, where anti-SARS-CoV-2-IgM and IgG are detectable as early
as 3 and 4 days post-illness onset (pio), respectively [3, 7]. Given the
seasonal circulation of several human coronaviruses (hCoV) including
229E, OC43, NL63 and HKU1, which are responsible for common cold
[9], coupled with individuals who have prior exposure to Severe
Acute Respiratory Syndrome Coronavirus (SARS-CoV) during the out-
break in 2003 [10], cross-reactivity amongst these genetically similar
viruses is inevitable, which may lead to confounding detection out-
comes when using recombinant proteins (sharing high homology)
[11]. Furthermore, the use of recombinant proteins, in addition to
high costs and storage constraints, may give rise to batch-to-batch
variations, which would greatly affect the reproducibility of immuno-
assays [12]. Thus, it remains crucial to ascertain the specificity and
sensitivity profiles for the development of efficient and precise
immunoassays. Lastly, specific regions on the viral proteins recog-
nised by virus-specific antibodies have yet to be further character-
ised, and this would be fundamental for a more targeted immune-
based approach.
This study reports a proteome-wide linear B-cell epitope screen of
SARS-CoV-2 S, envelope (E), membrane (M) and N virion proteins
using plasma samples collected from COVID-19 patients during the
SARS-CoV-2 outbreak in Singapore [13]. We present four immunodo-
minant peptides: S14P5, S20P2, S21P2 and N4P5, located on the S
and N proteins of SARS-CoV-2. We further propose the best peptide
combination with the highest specificity and sensitivity for determi-
nation of SARS-CoV-2 exposure. Moreover, the magnitude of the
humoral responses against these epitopes shows a strong positive
association with increasing disease severity.2. Materials and methods
2.1. Ethical approvals
The study design and protocols for COVID-19, recovered SARS and
seasonal hCoV patient cohorts were evaluated by National Healthcare
Group (NHG) Domain Specific Review Board (DSRB) and approved
S.N. Amrun et al. / EBioMedicine 58 (2020) 102911102919 102913under study numbers 2012/00917, 2020/00091 and 2020/00076,
respectively. Healthy donor samples were collected under study
numbers 2017/2806 and NUS IRB 04-140. Residual serum sample
from National Healthy Survey (NHS) collected in 2010 under study
number 006/2010 was used as a positive control in peptide-based
ELISA [14]. Written informed consent was obtained from participants
in accordance with the Declaration of Helsinki for Human Research.
2.2. Patients and sample collection
2.2.1. COVID-19 patients
Eighty-one patients who tested PCR-positive for SARS-CoV-2 in
nasopharyngeal swab samples and admitted to a public hospital in
Singapore were recruited into the study from January to March 2020
[13]. Demographic data, clinical and laboratory parameters, and clini-
cal severity during the hospitalisation period were retrieved from
patient records (Table 1). Patients were classified into three groups
based on clinical severity: mild (no pneumonia on chest radiographs
(CXR) at baseline and during hospital admission; clinical severity 0),
moderate (pneumonia on CXR without hypoxia; clinical severity 1),
and severe (pneumonia on CXR with hypoxia (desaturation to 94%);
clinical severity 2). Whole blood of patients was collected into BD
Vacutainer CPTTM tubes (BD Biosciences, #362753), and centrifuged
at 1700 g for 20min to obtain plasma fractions. Plasma samples were
categorised according to three timepoints: median 5 days post-illness
onset (pio), median 1014 days pio, and median 23 days pio.
2.2.2. Recovered SARS and seasonal hCoV patients
A total of 20 individuals previously diagnosed with SARS-CoV dur-
ing the outbreak in 2003 [15] were contacted and enrolled. PlasmaTable 1
Demographic and clinical data of COVID-19 patients.
Patients (n = 81)
Demographics
Age, years 45 (13)
Sex
Male 48 (59.3%)
Female 33 (40.7%)
Ethnicity
Chinese 68 (84.0%)
Others 13 (16.0%)
Comorbidities 28 (34.6%)
Diabetes 7 (8.6%)
Hypertension 15 (18.5%)
Others 11 (13.6%)
Vital signs at admission
Temperature, °C 37.7 (0.9)
Heart rate, beats/min 91.4 (16.6)
Respiratory rate, per min 18.4 (1.9)
Diastolic blood pressure, mmHg 97.5 (2.4)
Systolic blood pressure, mmHg 132.2 (18.5)
Oxygen saturation, % 77.8 (15.2)
Laboratory findings
Haemoglobin, g/dL 13.8 (1.6)
Haematocrit, % 40.8 (4.6)
Platelets, x 109/L 194.8 (69.8)
White blood cells, x 109/L 5.3 (3.0)
Lymphocytes, x 109/L 1.2 (0.6)
Neutrophils, x 109/L 4.3 (7.7)
Monocytes, x 109/L 0.6 (1.1)
C-reactive protein (CRP), mg/L 37.4 (55.7)
Creatinine, mmol/L 75.0 (45.3)
Lactate dehydrogenase (LDH), U/L 514.3 (298.4)
Alanine aminotransferase (ALT), U/L 34.6 (28.1)
Clinical outcome (clinical severity; group)
No pneumonia (0; mild) 34 (42.0%)
Pneumonia, without hypoxia (1; moderate) 28 (34.5%)
Pneumonia, with hypoxia (2; severe) 19 (23.5%)
Data represented as Mean (SD) or n (%). COVID-19: Coronavirus
Disease-19.fractions from recovered SARS individuals were isolated as described
above. Archived paired samples from hCoV patients collected
between 2012 and 2013 were also used in this study. This included
pre- and post-infected samples from seven alpha-CoV (229E/NL63)
and six beta-CoV (OC43) infections confirmed using the SeeGene
RV12 respiratory multiplex kit [16]. Demographic data were
retrieved from patient records (Supplementary Table 1).
2.3. Design of linear peptide libraries
SARS-CoV-2 and SARS-CoV full-length peptide sequences span-
ning the spike (S), envelope (E), membrane (M) and nucleocapsid (N)
were obtained from NCBI GenBank accession numbers MN908947.3
and NC_004718.3, respectively. Biotinylated linear peptides of
18-mer overlapping sequences of 10 residues were synthesised
(Mimotopes) and reconstituted in DMSO (Sigma-Aldrich, #D2650).
An initial screen was conducted using pooled peptide sets of five to
eight peptides per pool.
2.4. Plasma inactivation and peptide-based ELISA
Plasma fractions were treated with TritonTM X-100 (ThermoFisher
Scientific, #28314) to a final concentration of 1% for 2 h at room tem-
perature (RT) for virus inactivation [17]. Epitope screening was per-
formed using a peptide-based ELISA as previously described [1821].
Briefly, Maxisorp flat-bottom 96-well plates (ThermoFisher Scientific,
#442404) were coated overnight at 4 °C with 1:2000 dilution of Neu-
trAvidin protein (1mg/ml) (ThermoFisher Scientific, #31050) in PBS.
Plates were blocked with a 0.01% Polyvinyl Alcohol (PVA) (Sigma-
Aldrich, #341584) solution in 0.1% PBST (blocking buffer) before
addition of pooled or single biotinylated peptides (1:2000 dilution in
0.1% PBST), and inactivated plasma samples (1:1000 dilution in 0.1%
PBST). Goat anti-human IgM-HRP (Jackson ImmunoResearch, #109-
035-043, RRID: AB_2337581) or goat anti-human IgG-HRP (Jackson
ImmunoResearch, #109-035-088, RRID: AB_2337584) diluted in
blocking buffer was used for detection of peptide-bound antibodies.
For development, tetramethylbenzidine (TMB) substrate (Sigma-
Aldrich, #T8665) was added to the plates and the reaction was
stopped using 0.16M sulfuric acid (Merck, #1.00731.1000). Absor-
bance measurements were done using two wavelengths (450 nm and
690 nm) on an Infinite M200 plate reader (Tecan, firmware
V_2.02_11/06). In all steps, plates were incubated at RT for 1 h on a
rotating shaker and washed twice with 0.1% PBST in between steps.
2.5. Sequence alignment and computational modelling
Sequence alignment was conducted for each structural protein of
SARS-CoV-2 and SARS-CoV S, E, M and N using Clustal Omega (EMBL-
EBI, version 1.2.4). Structural data of immunodominant regions on
SARS-CoV-2 S and N proteins were retrieved from PDB 6VSB and
6YVO and were modelled in PyMol (Schrodinger, version 2.2.0).
2.6. Data and statistical analyses
Optical density (OD) values of samples were normalised to a posi-
tive control to account for plate-to-plate variations, and background
signals were subtracted. In the first screening phase of the peptide
pools, a cut-off value of mean + 3SD of healthy control samples was
used to single out individual peptides detected by COVID-19 patients.
For subsequent analyses with individual peptides, receiver operating
characteristic (ROC) curves for peptides to differentiate between
SARS-CoV-2 infections and others were performed, and the areas
under the curve (AUCs) were calculated for each peptide (supple-
mentary methods). The best threshold for each ROC curve was deter-
mined as the maximum of the Youden’s J statistic [22] with a
constraint that the threshold has to be a positive value
Fig. 1. Identification of IgG-specific linear B-cell epitopes on spike (S), envelope (E), membrane (M), and nucleocapsid (N) SARS-CoV-2 proteins with COVID-19 patient plasma. (ac)
Plasma samples of COVID-19 patients collected at timepoint of median 14 days post-illness onset (pio, n = 18), recovered SARS individuals (n = 20) and healthy donors (n = 22) were
pooled, respectively. (a) Pooled plasma samples (1:1000 dilution) were tested in a peptide-based ELISA of peptide pools covering SARS-CoV-2 S, E, M, and N proteins for IgG. Each
pool consists of 58 peptides, with an overlapping sequence of 10 amino acids. OD results are presented in a heatmap, with white and red colours denoting low and high OD values,
respectively. The cut-off for positive pools was derived from mean + 3SD of pooled healthy donors. (b) Individual peptides of the positive peptide pools in (a) were screened with
pooled plasma samples (1:1000 dilution) to determine the IgG hit peptides. OD results are presented in a heatmap, with white and red colours denoting low and high OD values,
respectively. (c) Peptide-binding response of pooled plasma samples (1:1000 dilution) against the corresponding hit peptides on SARS-CoV, with bar graphs presented as mean §
SEM, and dotted line denoting mean + 3SD of pooled healthy donors. All data in (ac) are of two independent experiments. (d,e) Diagrams showing the localisation of SARS-CoV-2
specific IgG peptides S6P2, S14P5, S20P2, S21P2, and N4P5 on (d) SARS-CoV-2 S (PDB: 6VSB), and (e) N (PDB: 6YVO) protein. Each monomer is denoted as either pink, blue, orange
or green. All peptides are annotated on the blue monomer.
102914 S.N. Amrun et al. / EBioMedicine 58 (2020) 102911102919(supplementary methods). For peptide combination analyses, logistic
regression models were used to model the combinatory effects of
two, three or four peptides’ OD readings towards the prediction of
SARS-CoV-2 infection from others as a binary outcome. The logistic
regression model fitted values were then used for ROC analysis to
identify the optimal thresholds (via Youden's J statistic) as well as
AUCs (supplementary methods). Data analyses were done using
GraphPad Prism (GraphPad Software, version 8.0.0). KruskalWallis
tests and post hoc tests using Dunn’s multiple comparison tests were
used to identify significant differences. Correlation analysis was car-
ried out using Spearman’s rank correlation. Absolute rho values
greater than 0.3 are considered to be a fair correlation [23]. P-values
less than 0.05 are considered significant.
2.7. Data availability
Data can be obtained upon request to the corresponding author.
3. Results
3.1. Immunodominant linear B-cell epitopes on SARS-CoV-2 S and N
proteome
In order to identify potential linear B-cell epitopes, pooled plasma
samples from 18 COVID-19 patients of the Singapore outbreak [13]
(Table 1) collected during the convalescent phase of median 14 days
pio were screened by peptide-based ELISA for IgG reactivity against a
pooled peptide library of five peptides, encompassing the entireSARS-CoV-2 structural proteome (Fig. 1a). Freshly drawn plasma
samples of 20 recovered SARS individuals and 22 healthy donors
were also assessed in parallel (Fig. 1a). While there was no specific
recognition on the E and M peptide pools by the COVID-19 patient
samples (Fig. 1a), several hits were identified in the S and N proteins,
based on the cut-off value using mean + 3SD of healthy controls. Posi-
tive pools S6, S14, S20, S21 from S glycoprotein, and N4 from N pro-
tein, were chosen for further characterisation of the specific peptide
recognised (Fig. 1a).
Within each pool of five overlapping peptides, further detailed
screening on each individual peptide allowed the identification of
distinct peptides highly recognised by IgGs present in the plasma
samples of COVID-19 patients. In addition to two reported peptide
epitopes S14P5 and S21P2 [21], peptide S6P2 from pool S6, peptide
S20P2 from pool S20, and peptide N4P5 from pool N4 were dominant
hits from their respective pools (Fig. 1b, Table 2 and Supplementary
Table 2). It is also noteworthy that IgG levels of recovered SARS and
healthy individuals in all of the assays were very low or negligible,
highlighting that COVID-19 patients recognised these peptides with
high specificity (Fig. 1a and b).
Given the high level of homology between SARS-CoV-2 and the
closely-related SARS-CoV [8, 24], pooled COVID-19 patient plasma
samples were also screened against the corresponding hit regions on
SARS-CoV S and N proteins to assess for potential cross-reactivity
(Fig. 1c and Table 2). Interestingly, while COVID-19 patient plasma
samples were able to recognise SARS-CoV versions of peptides S20P2
and N4P5, there was no binding to S6P2, alluding to the identification
of a potential SARS-CoV-2 specific epitope (Fig. 1c). The localisation of
Table 2
Peptide sequences of putative immunodominant SARS-CoV-2 IgG linear B-cell epitopes.
SARS-CoV-2 SARS-CoV Identity with SARS-CoV-2 (%)
Peptide Starting aa Ending aa Polypeptide sequence Starting aa Ending aa Polypeptide sequence
Spike (S) glycoprotein
S6P2 209 226 PINLVRDLPQGFSALEPL 201 218 QPIDVVRDLPSGFNTLKP 64.71
S14P5 553 570 TESNKKFLPFQQFGRDIA 537 554 VLTPSSKRFQPFQQFGRD 75.00
S20P2 769 786 GIAVEQDKNTQEVFAQVK 753 770 AAEQDRNTREVFAQVKQM 81.25
S21P2 809 826 PSKPSKRSFIEDLLFNKV 793 810 KPTKRSFIEDLLFNKVTL 93.75
Nucleocapsid (N) phosphoprotein
N4P5 153 170 NNAAIVLQLPQGTTLPKG 153 170 NNNAATVLQLPQGTTLPK 94.12
Sequences were obtained from GenBank (accession number: MN908947.3 and NC_004718.3), National Centre for Biotechnology Information (NCBI); aa: amino
acid, SARS-CoV: Severe Acute Respiratory Syndrome Coronavirus, SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2.
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Fig. 1d and e. All epitopes are located on the surface of the viral pro-
tein, except for S20P2, which is partially buried in the S protein 3D
structure (Fig. 1d).
3.2. SARS-CoV-2 epitopes can serve as highly specific and sensitive tools
Anti-SARS-CoV-2 antibody levels differ with infection phases,
with IgM being detected as early as 3 days pio [25]. To investigate
whether IgM epitopes could be identified with the same approach,
pooled patient plasma samples collected during the early acute
phase of median 5 days pio were screened with samples taken at
median 14 days pio (Supplementary Fig. 1a). Two positive pools,
S20 from S glycoprotein, and N10 from N protein, were detected
albeit at a lower recognition level at median 5 days pio, as com-
pared to samples taken during median 14 days pio (Supplementary
Fig. 1a). These peptide pools were further characterised to deter-
mine the specific regions. Peptides S20P4 and N10P1 were domi-
nant hits in their respective pools (Supplementary Fig. 1b andFig. 2. Specificity and sensitivity of putative IgG epitopes to detect anti-SARS-CoV-2 antibo
timepoints of median 10 days post-illness onset (pio, n = 59) and median 23 days pio (n = 66
plasma samples from recovered SARS patients (n = 20) and healthy donors (n = 22) were scre
S21P2, and N4P5. Data are shown as mean § SD of two independent experiments, with dotte
ity of putative epitopes to detect SARS-CoV-2-specific antibodies in plasma samples from CO
23 days pio (right panel). Specificity and sensitivity values were derived from a threshold
threshold value has to be positive. (c) Percentage recognition of epitopes during the timepoinsupplementary Table 2). Interestingly, COVID-19 patient plasma
samples were able to recognise both corresponding hit regions on
SARS-CoV S and N proteins, suggesting that these could be SARS
cross-reactive epitopes for IgM detection (Supplementary Fig. 1b).
Peptide S20P4 is localised on the surface of the S viral protein
(Supplementary Fig. 1d). However, when validated with a larger
number of patient samples, the putative epitopes were only recog-
nised by a minority of the COVID-19 patients, indicating that this
approach is inefficient for IgM detection (Supplementary Fig. 1E
and supplementary Table 3).
To further determine the longitudinal IgG profiling in a larger
cohort of COVID-19 patients (n = 79), individual plasma samples col-
lected at median 10 days pio (n = 59) and median 23 days pio (n = 66)
were assessed and compared. All the four putative epitopes, S14P5,
S20P2, S21P2, and N4P5, except S6P2, were distinctly recognised by
plasma samples from most COVID-19 patients (Fig. 2a). Strikingly,
there was no recognition to all epitopes by samples obtained from
patients infected with seasonal hCoV (baseline samples from patients
before infection were used as controls), and healthy donors (Fig. 2a).dies from COVID-19 patients. (a) Plasma samples from COVID-19 patients collected at
), sera from seasonal hCoV-infected patients (n = 13) either pre- or post-infection, and
ened at 1:1000 dilution against five IgG-specific putative epitopes: S6P2, S14P5, S20P2,
d lines indicating mean + 3SD of healthy donors. (b) Percentage specificity and sensitiv-
VID-19 patients during the timepoints of median 10 days pio (left panel) and median
determined by the maximisation of the Youden’s J statistic with a constraint that the
ts of median 10 days pio (black bars) and median 23 days pio (white bars).
Table 3
Receiver operating characteristic (ROC) profiles of IgG-specific SARS-CoV-2 linear B-cell
epitopes.
Peptide Threshold Specificity (%) Sensitivity (%) AUC Wilcoxon Padj value
Median 10 days pio
S6P2 1.153 100.00 3.39 0.847 <0.0001
S14P5 0.288 87.81 96.61 0.915 <0.0001
S20P2 0.328 95.12 88.14 0.974 <0.0001
S21P2 0.275 76.83 81.36 0.864 <0.0001
N4P5 0.313 100.00 96.61 0.994 <0.0001
Median 23 days pio
S6P2 0.022 96.34 12.12 0.895 <0.0001
S14P5 0.354 91.46 96.97 0.962 <0.0001
S20P2 0.360 98.78 95.46 0.993 <0.0001
S21P2 0.291 80.49 96.97 0.943 <0.0001
N4P5 0.335 100.00 98.49 0.999 <0.0001
pio: post-illness onset, AUC: area under curve, SARS-CoV-2: Severe Acute Respiratory Syndrome
Coronavirus 2.
102916 S.N. Amrun et al. / EBioMedicine 58 (2020) 102911102919However, cross-reactivity was observed for epitopes S14P5 and
S21P2 from one out of 20 recovered SARS individuals (Fig. 2a).
In order to define an optimal cut-off value for each peptide, we
used the Youden J statistical method, which determines the sensitiv-
ity and specificity profiles of the assay in one single test [22] (Meth-
ods, supplementary methods). This will guide the development of
diagnostic tests and estimate the probability of an informed decision.
Epitopes S20P2 and N4P5 exhibited specificity and sensitivity profiles
of about 90% (Fig. 2b, Table 3 and Supplementary Fig. 3). Both S14P5
and S21P2 have a moderate specificity and sensitivity level of >80%,
while S6P2 has a poor ability to correctly detect COVID-19 patients
with a sensitivity level of <10% (Fig. 2b, Table 3 and Supplementary
Fig. 3). S14P5 and N4P5 were consistently recognised by COVID-19
patients at a frequency of >97%, whereas the frequency of recognis-
ing S20P2 and S21P2 ranged between 81% and 88% at median
10 days pio (Fig. 2c). However, at median 23 days pio, the percentage
recognition for all four epitopes is >95%. Interestingly, when the vari-
ous peptide combinations of S14P5, S20P2, S21P2 and N4P5 were
predicted using bioinformatics tools (supplementary methods), theTable 4
Receiver operating characteristic (ROC) profiles of IgG-specific SA
Number of peptides in
combination
Peptide combination
Median 10 days pio
4 S14P5 + S20P2 + S21P2 + N4P5
3 S14P5 + S20P2 + N4P5
3 S20P2 + S21P2 + N4P5
3 S14P5 + S21P2 + N4P5
3 S14P5 + S20P2 + S21P2
2 S20P2 + N4P5
2 S14P5 + N4P5
2 S21P2 + N4P5
2 S20P2 + S21P2
2 S14P5 + S20P2
2 S14P5 + S21P2
Median 23 days pio
4 S14P5 + S20P2 + S21P2 + N4P5
3 S14P5 + S20P2 + N4P5
3 S20P2 + S21P2 + N4P5
3 S14P5 + S21P2 + N4P5
3 S14P5 + S20P2 + S21P2
2 S20P2 + N4P5
2 S14P5 + N4P5
2 S21P2 + N4P5
2 S20P2 + S21P2
2 S14P5 + S20P2
2 S14P5 + S21P2
pio: post-illness onset, AUC: area under curve, SARS-CoV-2: Sevespecificity and sensitivity of detection could approach 100% at
median 10 days (Table 4).
3.3. Epitope-specific IgG levels associate with disease severity
SARS-CoV-2 infected patients manifest different disease outcomes
that can be categorised into three groups: mild (no pneumonia, clini-
cal severity 0), moderate (pneumonia with no hypoxia, clinical sever-
ity 1), or severe (pneumonia with hypoxia, clinical severity 2) [26]. To
elucidate if anti-viral IgG responses at different days pio were associ-
ated with disease severity, antibody responses against the four highly
recognised epitopes were analysed based on disease severity (green
denotes mild, blue denotes moderate, and red denotes severe) (Sup-
plementary Fig. 2a and Fig. 3a). Surprisingly, only IgG responses at
median 23 days pio against epitopes S14P5, S21P2 and N4P5 were
higher in severe COVID-19 patients than in the mild and moderate
groups (Supplementary Fig. 2a and Fig. 3a). It was also observed that
IgG responses to epitopes S21P2 and N4P5 were associated with
pneumonia at median 23 days pio (Fig. 3b). In more severe cases withRS-CoV-2 linear B-cell epitopes used in combination.
Threshold Specificity (%) Sensitivity (%) AUC
0.500 100.00 100.00 1.000
0.500 100.00 100.00 1.000
0.500 100.00 100.00 1.000
0.804 100.00 98.30 0.997
0.414 92.70 91.50 0.981
0.269 98.80 100.00 1.000
0.803 100.00 98.30 0.997
0.481 98.80 98.30 0.992
0.407 92.70 91.50 0.982
0.503 93.90 88.10 0.975
0.373 84.10 96.60 0.929
0.500 100.00 100.00 1.000
0.500 100.00 100.00 1.000
0.500 100.00 100.00 1.000
0.794 100.00 98.50 0.999
0.353 98.80 100.00 0.998
0.500 100.00 100.00 1.000
0.820 100.00 98.50 0.999
0.792 100.00 98.50 0.999
0.307 97.60 97.00 0.998
0.278 97.60 100.00 0.997
0.485 92.70 97.00 0.971
re Acute Respiratory Syndrome Coronavirus 2.
Fig. 3. Association of anti-SARS-CoV-2 antibody response of COVID-19 patients with clinical severity during SARS-CoV-2 infection. Antibody profiles of COVID-19 patients at time-
point of median 23 days post-illness onset (pio, n = 66) against significant IgG peptides under different clinical measures of (a) disease severity, (b) pneumonia, and (c) intensive
care unit (ICU) admission and oxygen supply requirement. Samples in (a) were classified based on severity with green denoting mild (clinical severity 0; n = 28), blue denoting mod-
erate (clinical severity 1; n = 22), and red denoting severe (clinical severity 2; n = 16). Data are presented as mean § SD of two independent experiments. Negative and positive
observations in (b-c) are denoted as - and +, respectively. Statistical analysis was carried out using Kruskal-Wallis tests, followed by post hoc Dunn’s multiple comparison tests.
(**P<001, ***P<0001).
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IgG levels to S14P5 at median 23 days pio were also significantly
higher (Fig. 3c). Correlation analyses of these epitopes with other
clinical parameters of severity showed positive association with C-
reactive protein (CRP), lactate dehydrogenase (LDH) and lymphope-
nia (Supplementary Fig. 2bd).
4. Discussion
The development of sensitive and specific immunoassays that can
determine SARS-CoV-2 exposure, and serve as sero-epidemiological
surveillance tools would greatly help to control virus transmission. In
this study, four immunodominant IgG-specific SARS-CoV-2 linear
epitopes, S14P5, S20P2, S21P2 and N4P5, located on the S and N viral
proteins were described. The S and N antigens are immunodominant
amongst coronavirus antigens, and are commonly used in the devel-
opment of serological assays against coronaviruses [5, 8, 27]. Sequen-
ces of these epitopes are well conserved across multiple SARS-CoV-2
strains [21] (Supplementary Table 4), with no detectable cross-reac-
tivity against seasonal hCoV and recovered SARS individuals, despitea high level of homology with the corresponding regions on SARS-
CoV (Table 2) [11]. Moreover, sequences of several identified epitopes
overlap either completely or partially with reported SARS-CoV B-cell
linear epitopes at regions QQFGRD in S14P5, FIEDLLFNKVTLADAGF in
S21P2, and QLPQGTTLPKG in N4P5 [28]. Corroborating a recent study,
no response was also detected against the SARS-CoV S protein by
recovered SARS patients who were infected 17 years ago [21], sug-
gesting that antibodies against SARS-CoV linear epitopes are short-
lived [29]. As there is currently no active SARS-CoV transmission, it
remains elusive whether antibodies against SARS-CoV would react
with these immunodominant SARS-CoV-2 epitopes and generate
false positive responses. We demonstrated in this report that the best
performing linear B-cell epitopes, S20P2 and N4P5, could correctly
discriminate SARS-CoV-2 from seasonal coronavirus infection in
patients, with a specificity and sensitivity levels of >90% for single
peptide detection.
Interestingly, simulation on the combinatorial use of two or more
peptides can approach 100% sensitivity and specificity for the detec-
tion of COVID-19 patients. This is an important aspect for the design
of point-of-care tests (POCTs) where the combination of two peptides
102918 S.N. Amrun et al. / EBioMedicine 58 (2020) 102911102919(i.e. S20P2 plus N4P5) could allow for rapid IgG detection with a high
level of specificity and sensitivity. This remains as one of the current
limitation in the development of POCTs based on single SARS-CoV-2
proteins. Furthermore, the use of recombinant proteins may lead to
false positive results and hamper specificity of the immune-based
assays due to high level of cross-reactivities between SARS-CoV-2
and other human coronaviruses such as the closely-related SARS-CoV
[11, 24, 30]. For instance, in a hypothetical scenario, a test that is 90%
specific and 100% sensitive is used to screen a population of 10,000
persons without COVID-19 and 100 persons with COVID-19. In this
scenario, 1100 persons will test positive, of which 1000 are false posi-
tives, creating a larger burden for follow-up diagnostic assays and
potentially unnecessary quarantine measure.
The prevalence of human coronaviruses differ geographically and
in different populations [9, 31]. As a result, this will influence the
specificity and/or sensitivity of the immune-based assays due to the
different cut-off values taken from various healthy controls around
the world. However, the use of specific epitopes reported in this
study may overcome the various specificity and sensitivity issues.
Moreover, the use of high purity peptide-based immunoassays can
overcome batch-to-batch inconsistencies resulting from variations in
protein refolding and storage stability. Although the samples
screened in this study were collected at median 10 days pio (with
hospital admission of median 5 days pio), the value of developing
POCTs with these immunodominant IgG epitopes would still be use-
ful in identifying undiagnosed asymptomatic carriers. In the event
that SARS-CoV-2 transmission becomes seasonal, this rapid testing
will allow medical workers to quickly decide the best course of action
and provide the critically-ill patients with the best chance of survival.
The wide spectrum of COVID-19 clinical severity ranges from
asymptomatic, to a mild upper respiratory tract infection, to viral
pneumonia, and to death from respiratory failure or associated com-
plications [8, 25, 32, 33]. Our study revealed that IgG levels against
epitopes S14P5, S21P2 and N4P5 in COVID-19 patients were associ-
ated with disease severity, confirming recent studies that reported an
association of antibody levels against the S protein with disease
severity [3, 5, 7, 26]. Moreover, within the severe group, high anti-
body levels against these linear B-cell epitopes were also detected
by patients who either developed pneumonia or were admitted
into the ICU. SARS-CoV-2 is just one of the many pathogens that can
cause severe pneumonia. Ideally, screening an independent cohort
with individuals experiencing severe pneumonia against these IgG
epitopes, followed by validation with pathogen testing and other
clinical data would be useful to confirm or exclude the diagnosis of
COVID-19.
Antibody levels against these epitopes also correlated with clinical
laboratory parameters such as CRP and LDH levels, which are ele-
vated in severe COVID-19 patients [34, 35]. High IgG levels against
epitope N4P5 correlated with lymphopenia, a phenomenon found in
COVID-19 patients [36]. One plausible hypothesis for these associa-
tions is that severe patients had a higher viral load during the early
infection phase that resulted in higher antibody responses. While a
causality link between antibody response and enhanced severity
remains to be determined, it is also possible that high specific-anti-
body levels may contribute to an enhanced lung inflammation in
COVID-19 patients. Such an observation was reported in SARS-CoV-
infected monkeys treated with an anti-S protein monoclonal anti-
body [37]. In addition, there could also be a higher level of non-neu-
tralising antibody responses in severe patients that may lead to a
detrimental consequence such as antibody dependant enhancement,
which was demonstrated in vitro using SARS-CoV patients serum
samples [38]. Nevertheless, these putative epitopes can serve as use-
ful indicators on the degree of immunopathology in COVID-19
patients, and validation on a larger cohort remains necessary.
Altogether, in view of the recent studies demonstrating the pres-
ence of mutation and deletions in SARS-CoV-2, the identification ofmultiple epitopes for the detection of SARS-CoV-2 infection allows
for constant refinement of the peptide sequences to be used in sero-
logical assays [39, 40]. An advantage of the epitopes reported in this
study is the low rate of potential mutations, with a highest mutation
rate of 135% for epitope S21P2 (16 SNP in 236 sequences out of
17,462 deposited complete genomes), and below 019% for all other
peptides (Supplementary Table 4). An immediate application of these
peptide epitopes could be developed as paper-based lateral flow
assays [25]. Ideally, the implementation of peptides on POCTs would
be easier and cost effective than protein-based systems. However, it
is important to note that serological POCTs should not replace RT-
PCR especially in the diagnosis of an early acute SARS-CoV-2 infection
due to the delayed antibody response [25, 41, 42]. Nonetheless, the
identification of IgG-specific epitopes on the S and N viral proteins
expands the tool box needed for sero-epidemiological studies and
vaccine assessment.
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